Samsung Biologics (KRX:207940) plans to issue 2.27 million new common shares at a par value of 2,500 won per share through a general public offering of forfeited shares after shareholder allotment, bringing the total value of the allotment to 5.68 billion won.
Funds raised via the issuance will be used primarily to acquire securities issued by other corporations, with 294.8 billion won allocated for facility investment, according to a Friday filing with the Korea Exchange.
Shares of Samsung Biologics fell nearly 6% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments